1. Home
  2. PRTA vs JFIN Comparison

PRTA vs JFIN Comparison

Compare PRTA & JFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRTA
  • JFIN
  • Stock Information
  • Founded
  • PRTA 2012
  • JFIN 2011
  • Country
  • PRTA Ireland
  • JFIN China
  • Employees
  • PRTA N/A
  • JFIN N/A
  • Industry
  • PRTA Biotechnology: Pharmaceutical Preparations
  • JFIN Finance: Consumer Services
  • Sector
  • PRTA Health Care
  • JFIN Finance
  • Exchange
  • PRTA Nasdaq
  • JFIN Nasdaq
  • Market Cap
  • PRTA 472.1M
  • JFIN 472.3M
  • IPO Year
  • PRTA N/A
  • JFIN 2019
  • Fundamental
  • Price
  • PRTA $10.45
  • JFIN $8.94
  • Analyst Decision
  • PRTA Buy
  • JFIN
  • Analyst Count
  • PRTA 9
  • JFIN 0
  • Target Price
  • PRTA $17.71
  • JFIN N/A
  • AVG Volume (30 Days)
  • PRTA 567.7K
  • JFIN 83.4K
  • Earning Date
  • PRTA 11-06-2025
  • JFIN 11-20-2025
  • Dividend Yield
  • PRTA N/A
  • JFIN 8.87%
  • EPS Growth
  • PRTA N/A
  • JFIN 33.85
  • EPS
  • PRTA N/A
  • JFIN 4.21
  • Revenue
  • PRTA $11,786,000.00
  • JFIN $908,895,698.00
  • Revenue This Year
  • PRTA N/A
  • JFIN N/A
  • Revenue Next Year
  • PRTA $672.02
  • JFIN N/A
  • P/E Ratio
  • PRTA N/A
  • JFIN $2.14
  • Revenue Growth
  • PRTA N/A
  • JFIN 8.19
  • 52 Week Low
  • PRTA $4.32
  • JFIN $5.18
  • 52 Week High
  • PRTA $18.65
  • JFIN $19.23
  • Technical
  • Relative Strength Index (RSI)
  • PRTA 56.63
  • JFIN 36.44
  • Support Level
  • PRTA $10.02
  • JFIN $8.81
  • Resistance Level
  • PRTA $11.17
  • JFIN $9.65
  • Average True Range (ATR)
  • PRTA 0.56
  • JFIN 0.50
  • MACD
  • PRTA -0.07
  • JFIN 0.01
  • Stochastic Oscillator
  • PRTA 37.37
  • JFIN 27.09

About PRTA Prothena Corporation plc

Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

About JFIN Jiayin Group Inc.

Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.

Share on Social Networks: